Tresiba (Insulin Degludec) for Adolescent Girls Ages 12 to 17: Transitioning to Adult Diabetes Care

Why the Transition from Pediatric to Adult Care Is a Medical Risk Zone for Teen Girls

The handoff from a pediatric endocrinology team to an adult diabetes provider is rarely smooth. For adolescent girls, it comes during a period already defined by fluctuating estrogen and progesterone, a shifting body composition, and often a first encounter with new stressors like college, independent living, or work. Studies consistently show glycemic control deteriorates during this window.

A 2018 analysis published in Diabetes Care found that HbA1c rose by an average of 0.7% in the year following transfer to adult services, with the steepest increases in young women who experienced a gap in care of six months or longer. That is not a trivial change: each 1% rise in HbA1c is associated with a significantly higher risk of diabetic retinopathy and nephropathy over a 10-year horizon.

The reasons are layered. Pediatric teams know a patient's family, growth chart, and school schedule. Adult providers inherit a stranger. Insurance changes happen. Appointment no-shows spike. And for girls specifically, puberty brings a physiological insulin resistance that does not resolve until the mid-twenties in some women with type 1 diabetes.

What Changes Physiologically at Puberty for Girls With Diabetes

During Tanner stages III through V, growth hormone secretion increases dramatically, and growth hormone directly antagonizes insulin signaling at the receptor level. This is not behavioral. A girl who had stable glucose control at age 10 on a given basal dose will need more insulin by age 13 regardless of diet or activity choices.

Estrogen has a biphasic effect. In the follicular phase of the menstrual cycle, estrogen tends to improve peripheral insulin sensitivity. In the luteal phase, rising progesterone works against insulin, raising fasting and post-meal glucose levels in many girls with type 1 diabetes. A study in Diabetologia confirmed that insulin requirements in women with type 1 diabetes are measurably higher in the luteal phase compared with the follicular phase.

Why Tresiba's Flat Profile Matters During Hormonal Fluctuation

Most basal insulins have a pronounced peak or variable absorption. Tresiba forms a soluble multi-hexamer depot under the skin and releases insulin in a slow, near-peakless manner over approximately 42 hours. The BEGIN trials program demonstrated that insulin degludec produces significantly less day-to-day variability in glucose-lowering effect compared with insulin glargine U-100. For a teenager whose hormonal environment is already unpredictable, a more stable basal action profile reduces one source of variability she cannot control.

How Tresiba Dosing Works for Adolescent Girls (Ages 12 to 17)

Tresiba is dosed once daily at any consistent time of day. That flexibility is not a minor detail for a teenager whose schedule changes between school days, weekends, and summers. The FDA prescribing information for Tresiba specifies that the injection time can be shifted by up to 8 hours without clinically meaningful impact on 24-hour coverage, which is directly relevant to irregular adolescent schedules.

Starting Dose When Transitioning Basal Insulins

When switching from another long-acting basal insulin (glargine or detemir) to Tresiba on a unit-for-unit basis, most adolescents start at the same total daily dose. If switching from twice-daily detemir, the total daily detemir dose is converted to once-daily Tresiba at the same unit count. The prescribing team then adjusts based on fasting glucose targets over the first two weeks, because Tresiba takes 2 to 3 days to reach full pharmacodynamic steady state.

Puberty-Adjusted Dose Ranges

Before puberty, most children with type 1 diabetes need 0.4 to 0.6 units per kilogram per day (total insulin). During active puberty, that figure commonly rises to 0.7 to 1.0 units per kilogram per day or higher. The basal component typically accounts for 40 to 50% of the total daily dose. A 60-kg teenager in mid-puberty may therefore need 20 to 30 units of Tresiba as basal alone, compared with 12 to 15 units before puberty began.

Your adult provider should reassess your total daily dose at every visit during the transition period. If your new clinic does not have your pediatric records, bring a printed summary of your last three HbA1c values, your current basal and bolus doses, and your continuous glucose monitor (CGM) time-in-range data if you use one.

The U-100 vs. U-200 Formulation Question

Tresiba comes in both U-100 (100 units/mL) and U-200 (200 units/mL, FlexTouch pen only). Most adolescents use U-100. The U-200 pen is designed for adults who require more than 80 to 100 units of basal insulin daily and is rarely appropriate at the start of the transition period. Mixing up formulations is a real safety risk: the U-200 pen delivers twice the dose per unit dialed. Confirm with your pharmacist which concentration you have been dispensed each time you fill a prescription.

The Menstrual Cycle and Insulin Needs: A Practical Guide for Teen Girls on Tresiba

Hormonal fluctuation across the menstrual cycle is one of the most underappreciated drivers of glucose variability in adolescent and young adult women with type 1 diabetes. Many girls are never told this is a physiological pattern, not a failure of self-management.

Follicular Phase (Days 1 to 13)

From the start of your period through ovulation, estrogen is the dominant hormone. Insulin sensitivity is generally higher. Some women find their fasting glucose is easier to control and they need slightly less insulin to cover meals. For Tresiba users, no dose change is typically needed in the follicular phase unless persistent lows appear on CGM data.

Luteal Phase (Days 14 to 28, Approximately)

After ovulation, progesterone rises and insulin resistance increases. Research in the Journal of Diabetes Science and Technology found that women with type 1 diabetes required an average of 12 to 15% more total daily insulin in the luteal phase to achieve the same glucose targets as in the follicular phase. For some women the difference is larger, especially in the 3 to 5 days before menstruation.

A practical approach: track your CGM time-in-range or fasting glucose by cycle day for two to three months. If a consistent pattern of higher fasting glucose appears in the second half of your cycle, discuss a small temporary increase in your Tresiba dose (typically 1 to 3 units, or roughly 10%) with your provider during those days.

Menstruation Itself

The first 1 to 2 days of menstruation often bring a sharp drop in insulin resistance as progesterone falls. Some girls experience rebound hypoglycemia at the start of their period. If you use a CGM, look for this pattern. It is a known, documented phenomenon, not a sign that something is wrong with your diabetes management.

PCOS, Insulin Resistance, and Tresiba in Teenage Girls

Polycystic ovary syndrome affects an estimated 6 to 12% of reproductive-age women in the United States and is frequently first identified in adolescence. PCOS is defined partly by hyperandrogenism and often involves significant insulin resistance independent of body weight. A teenage girl with PCOS and type 2 diabetes (or prediabetes) represents a distinct clinical picture from a girl with type 1.

For girls with type 2 diabetes and PCOS who require basal insulin, Tresiba addresses the basal glucose elevation driven by hepatic glucose output overnight. It does not directly treat the androgen excess or menstrual irregularity of PCOS. Metformin, when tolerated, remains first-line for type 2 diabetes in adolescents and addresses insulin resistance at a mechanistic level that basal insulin alone does not. If your provider has added Tresiba to metformin, the combination is rational but your total daily insulin requirement may be lower than for a girl without PCOS-related metformin use, because metformin reduces hepatic glucose output through a separate pathway.

The PCOS-T1D overlap: A subset of girls with type 1 diabetes also develop PCOS, and the two conditions interact in ways that make glucose management harder. The higher androgen levels in PCOS worsen insulin resistance beyond what puberty alone causes, and the erratic menstrual cycles make the cycle-phase tracking strategy above less predictable. Studies suggest the prevalence of PCOS is 2 to 3 times higher in women with type 1 diabetes compared with the general population, likely because chronic hyperinsulinemia from intensive insulin therapy stimulates ovarian androgen production. If you have type 1 diabetes and irregular periods, acne, or excess hair growth, ask your provider about PCOS screening. This combination changes how aggressively insulin resistance should be addressed.

Pregnancy, Lactation, and Contraception: What Teen Girls on Tresiba Must Know

This section is required reading before you make any decisions about contraception or family planning.

Pregnancy Safety: What the Data Actually Show

Tresiba does not have an FDA pregnancy letter category. Under the post-2015 labeling format, the prescribing information states that available data from clinical trials and post-marketing experience with insulin degludec use in pregnancy are insufficient to establish a drug-associated risk for major birth defects or miscarriage. Animal studies conducted at doses up to 10 times the human dose did not show embryotoxicity or teratogenicity, but animal data do not reliably predict human outcomes.

In practice, most reproductive endocrinologists and maternal-fetal medicine specialists prefer insulin glargine (Lantus, Basaglar) or NPH insulin in pregnancy because those agents have a longer record of human use during gestation. The decision to continue Tresiba through a pregnancy is individualized. If you are actively trying to conceive, discuss switching to an agent with more pregnancy-specific human data before conception, not after a positive test.

Unintended Pregnancy Risk in Teenagers With Diabetes

Unintended pregnancy in adolescents with type 1 or type 2 diabetes carries substantially higher maternal and fetal risk than in teenagers without diabetes. Neural tube defects, cardiac malformations, and macrosomia all increase with poor glycemic control in the first trimester, a period when many teenagers do not yet know they are pregnant. ACOG Practice Bulletin on Pregestational Diabetes Mellitus recommends that all women with pregestational diabetes use effective contraception until they have achieved an HbA1c below 6.5% and have received preconception counseling.

This is not a judgment about whether a teenager should or should not be sexually active. It is a medical safety statement: reliable contraception matters more for a young woman with diabetes than for her peers without the condition.

Effective contraceptive options that are compatible with type 1 or type 2 diabetes include:

• Progestin-only pills (no estrogen-related VTE risk)
• Hormonal IUDs (levonorgestrel; minimal systemic absorption, no meaningful effect on glycemic control in most users)
• Copper IUD (non-hormonal; appropriate if you prefer no hormonal exposure)
• Implant (etonogestrel; very low systemic dose, generally glycemically neutral)

Combined estrogen-progestin pills are not contraindicated in most teenage girls with diabetes, but the estrogen component may slightly worsen insulin resistance and should be discussed with a provider who knows your cardiovascular risk profile.

Lactation

Insulin degludec transfers into breast milk in very small amounts. The Tresiba prescribing information notes that because insulin is a peptide, it is expected to be degraded in the infant's gastrointestinal tract and is unlikely to cause harm. Breastfeeding itself lowers insulin requirements in women with type 1 diabetes by roughly 20 to 25% compared with the third trimester, and hypoglycemia during nursing is a documented risk. If you are 17 or 18, postpartum, and breastfeeding on Tresiba, work with your provider to reduce your basal dose proactively and keep fast-acting glucose (glucose tablets or juice) within reach during feeds.

Who This Is Right For, and Who Should Reconsider

Tresiba Is a Reasonable Choice If You Are

A teenage girl (ages 12 to 17) with type 1 or type 2 diabetes who needs once-daily basal insulin coverage, particularly if you have had issues with unpredictable hypoglycemia on glargine or detemir. The lower day-to-day glucose variability demonstrated in the BEGIN Basal-Bolus Type 1 trial (n=629) translated to fewer nocturnal hypoglycemic episodes compared with glargine, a clinically meaningful difference for a teenager sleeping alone in a college dorm.

Tresiba also suits girls whose schedules change week to week. The 8-hour injection-time flexibility is genuinely useful for shift workers, students with variable class schedules, and athletes whose training blocks shift seasonally.

Consider a Different Approach If

Your insurance formulary requires step therapy through glargine before covering Tresiba, and cost will create adherence barriers. A basal insulin you can afford and consistently obtain is better than an optimal one that runs out mid-month. During the transition period, your new adult provider may need to write a prior authorization letter documenting medical necessity if you are switching from a pediatric formulary.

Girls in very early puberty (Tanner stage II) with still-low total daily insulin requirements may not notice a practical difference between Tresiba and glargine. The pharmacokinetic advantage of degludec is most apparent when basal doses are higher (generally above 20 units daily) and when hypoglycemia is a recurring problem.

Navigating the Actual Handoff: Practical Steps for Teen Girls and Their Parents

The transition is not a single appointment. The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines recommend beginning transition preparation at age 14 to 15, using a structured readiness checklist, and completing the formal transfer by age 18 at the latest, with a clear overlap period during which both teams remain available.

What to Bring to Your First Adult Endocrinology Visit

• Printed or digital copy of your last pediatric clinic letter (ask your pediatric team to write a transition summary letter, not just release records)
• List of current insulin doses: Tresiba dose in units, bolus insulin type and your insulin-to-carb ratios by meal, and any correction factor
• Most recent HbA1c result and date
• CGM download covering the past 14 to 30 days (most CGM apps let you generate a PDF ambulatory glucose profile report)
• Current pharmacy contact and insurance card
• Any PCOS, thyroid, or celiac diagnoses (autoimmune conditions cluster with type 1 diabetes in girls at a higher rate than in boys)

Questions to Ask Your New Adult Provider

Ask explicitly whether they have experience managing young women with type 1 diabetes across the menstrual cycle. Ask whether the practice has a dietitian familiar with carbohydrate counting for adolescents. Ask what the after-hours contact protocol is for urgent glucose emergencies. These are not demanding questions. They are appropriate clinical safety checks.

The Gap in Care Is the Danger Zone

A Canadian cohort study of 1,507 young adults found that each additional month without a diabetes provider visit in the transition period was associated with a 0.04% increase in HbA1c. A six-month gap accumulates to roughly a 0.25% rise. Over years, that compounds into microvascular risk. If your adult appointment is more than three months away, ask your pediatric team to extend one additional prescription refill and maintain phone or portal access until the new relationship is established.

Evidence Gaps Specific to Adolescent Girls on Tresiba

Women have been under-represented in diabetes pharmacology trials throughout clinical research history, and adolescent girls are almost entirely absent as a studied subgroup. The BEGIN trial program recruited predominantly adult participants. The pediatric Tresiba trials included children and adolescents ages 1 to 17 but did not analyze outcomes by sex or by pubertal stage, meaning the cycle-phase dosing guidance above is extrapolated from adult women's physiology studies, not from trials in 14-year-old girls on Tresiba specifically.

This matters. A 15-year-old girl in Tanner stage IV is physiologically distinct from a 35-year-old woman. The evidence base treats them as equivalent for dosing purposes. Until sex-stratified and puberty-stage-stratified data exist, the honest clinical answer is that cycle-phase adjustments on Tresiba are informed by physiological reasoning and adult women's data, not by a trial designed for adolescent girls.

"The transition period is when we lose young women to good diabetes care," says Maya Okafor, MD, WomanRx medical reviewer and board-certified OB-GYN. "The endocrinology team changes, the pharmacy changes, sometimes the insulin brand changes because of formulary differences, and nobody has told the patient that her menstrual cycle is about to start affecting her glucose as much as her diet does. That silence is a clinical failure we can fix with one conversation."